Male breast carcinoma: An evaluation of prognostic factors contributing to a poorer outcome

Cancer

Volumn 77, Issue 3, 1996, Pages 490-498

  Joshi, Megha G ^a   Lee, Arthur K C ^a,e   Loda, Massimo ^a,e   Camus, Mauricio G ^d   Pedersen, Carl ^c   Heatley, Gerald J ^b   Hughes, Kevin S ^a  

^a LAHEY HOSPITAL AND MEDICAL CENTER   (United States)

^b Lahey Hospital Medical Center   (Canada)

^c HARTFORD HOSPITAL   (United States)

^d BETH ISRAEL DEACONESS MEDICAL CENTER   (United States)

^e HARVARD MEDICAL SCHOOL   (United States)

Author keywords

c erbB 2; dermal lymphatic invasion; invasive cribriform carcinoma; male breast carcinoma; nodal metastases; p53; Paget's disease of the nipple

Indexed keywords

DIETHYLSTILBESTROL; ESTROGEN RECEPTOR; MEGESTROL ACETATE; ONCOPROTEIN; PROGESTERONE RECEPTOR; PROTEIN P53; TAMOXIFEN;

ADULT; AGED; ARTICLE; BREAST CARCINOMA; CANCER CHEMOTHERAPY; CANCER INVASION; CANCER RADIOTHERAPY; CANCER SIZE; CANCER STAGING; CANCER SURGERY; CANCER SURVIVAL; CARCINOMA IN SITU; CLINICAL ARTICLE; CLINICAL FEATURE; HISTOLOGY; HISTOPATHOLOGY; HUMAN; HUMAN TISSUE; INTRADUCTAL CARCINOMA; LYMPH NODE METASTASIS; MALE; MALE BREAST; PRIORITY JOURNAL; PROGNOSIS; PROTEIN EXPRESSION;

EID: 0030029750     PISSN: 0008543X     EISSN: None     Source Type: Journal    
DOI: 10.1002/(sici)1097-0142(19960201)77:3<490::aid-cncr10>3.0.co;2-%23     Document Type: Article

References (60)

1. Heller KS, Rosen PP, Schottenfeld D, Ashikari R, Kinne DW. Male breast cancer: a clinicopathologic study of 97 cases. Ann Surg 1978;188:60-5.
2. Crichlow RW, Galt SW. Male breast cancer. Surg Clin North Am 1990;70:1165-77.
3. Borgen PI, Wong GY, Vlamis V, Potter C, Hoffman B, Kinne DW, et al. Current management of male breast cancer: a review of 104 cases. Ann Surg 1992;215:451-459.
4. Scheike O. Male breast cancer. 6. Factors influencing prognosis. Br J Cancer 1974;30:261-71.
5. Langlands AO, Maclean N, Kerr GR. Carcinoma of the male breast: report of a series of 88 cases. Clin Radiol 1976;27:21-5.
6. Liechty RD, Davis J, Gleysteen J. Cancer of the male breast. Forty cases. Cancer 1967;20:1617-24.
7. Stalsberg H, Thomas DB, Rosenblatt KA, Jimenez LM, McTiernan A, Stemhagen A, et al. Histologic types and hormone receptors in breast cancer in United States men: a population-based study in 282 men. Cancer Causes and Control 1993;4:143-51.
8. Silfverswärd C, Gustafsson JA, Gustafsson SA, Humla S, Nordenskjöld B, Wallgren A, et al. Estrogen receptor concentrations in 269 cases of histologically classified human breast cancer. Cancer 1980;45:2001-5.
9. Visfeldt J, Scheike O. Male breast cancer. I. Histologic typing and grading of 187 Danish cases. Cancer 1973;32:985-90.
10. Greening WP, Aichroth PM. Cancer of the male breast. Br J Cancer 1965;19:92-100.
11. Williams IG. Carcinoma of the male breast. Lancet 1942:701-3.
12. Morimoto T, Komaki K, Yamakawa T, Tanaka T, Oomine Y, Konishi Y, et al. Cancer of the male breast. J Surg Oncol 1990;44:180-4.
13. Bloom HJG, Richardson WW. Histological grading and prognosis in breast cancer: a study of 1409 cases of which 359 have been followed for 15 years. Br J Cancer 1957;11:359-77.
14. Scarff RW, Torloni H. Histologic typing of breast tumors (International Histologic Classification of Tumors, no. 2). Geneva: World Health Organization, 1968.
15. Elston CW. Grading of invasive carcinoma of the breast. In: Page DL, Anderson TJ, editors. Diagnostic histopathology of the breast. New York: Churchill Livingstone, 1987:300-11.
16. Spiessl B, Beahrs OH, Hermanek P, Hutter RVP, Scheibe O, Sobin LH, et al., editors. UICC TNM classification of malignant tumours. 4th ed. 2nd rev. Berlin: Springer-Verlag, 1992.
17. 53 overexpression in node negative breast carcinoma: preliminary studies support cautious optimism (editorial). J Natl Cancer Inst 1993;85:176-7.
18. Cartun RW, Pedersen CA. An immunocytochemical technique offering increased sensitivity and lowered cost with a streptavidin-horseradish peroxidase conjugate. Histotechnology 1989;12:273-7.
19. Lee AKC, Wiley B, Loda M, Bosari S, Dugan JM, Hamilton W, et al. DNA ploidy, proliferation, and neu-oncogene protein overexpression in breast carcinoma. Mod Pathol 1992;5:61-7.
20. Lee ET. Statistical methods for survival data analysis. Belmont, CA: Lifetime Learning, 1980.
21. Tarone R, Ware J. On distribution-free tests for equality of survival distributions. Biometrika 1977;64:156-60.
22. Rothman KJ, Boice JD Jr. Epidemiological analysis with a programmable calculator. Boston: Epidemiology Resources, 1982.
23. Camus MG, Joshi MG, Mackarem G, Lee AKC, Rossi RL, Munson JL, et al. Ductal carcinoma in situ of the male breast. Cancer 1994;74:1289-93.
24. Slack RWT. The survival rate of men with carcinoma of the breast. Br J Surg 1975;62:963-5.
25. van Geel AN, van Slooten EA, Mavrunac M, Hart AAM. A retrospective study of male breast cancer in Holland. Br J Surg 1985;72:724-7.
26. Page DL, Dixon JM, Anderson TJ, Lee D, Stewart HJ. Invasive cribriform carcinoma of the breast. Histopathology 1983;7:525-36.
27. Venable JG, Schwartz AM, Silverberg SG. Infiltrating cribriform carcinoma of the breast: A distinctive clinicopathologic entity. Hum Pathol 1990;21:333-8.
28. Haagensen CD. Carcinoma of the male breast. In: Diseases of the breast. 3rd ed. Philadelphia: W.B. Saunders Co., 1986:976-90.
29. Carter CL, Allen C, Henson DE. Relation of tumor size, lymph node status, and survival in 24,740 breast cancer cases. Cancer 1989;63:181-7.
30. Rouviere H. Anatomic des Lymphatiques de l'Home. Paris: Masson, 1932.
31. Haagensen CD. Anatomy of the mammary glands. In: Diseases of the breast. 3rd ed. Philadelphia: W.B. Saunders Co., 1986:25-46.
32. Turner-Warwick RT. The lymphatics of the breast. Br J Surg 1959;46:574-82.
33. Treves N. Inflammatory carcinoma of the breast in the male patient. Surgery 1953;34:810-20.
34. Sherry MM, Johnson DH, Page DL, Greco FA, Hainsworth JD. Inflammatory carcinoma of the breast. Clinical review and summary of the Vanderbilt experience with multi-modality therapy. Am J Med 1985;79:355-64.
35. Fisher ER, Gregorio RM, Fisher B, Redmond C, Vellios F, Sommers SC. The pathology of invasive breast cancer. Cancer 1975;36:1-85.
36. Lucas FV, Perez-Mesa C. Inflammatory carcinoma of the breast. Cancer 1978;41:1595-1605.
37. Ellis DL, Teitelbaum SL. Inflammatory carcinoma of the breast. A pathologic definition. Cancer 1974;33:1045-7.
38. Cunha F, Andre S, Soares J. Morphology of male breast carcinoma in the evaluation of prognosis. Path Res Pract 1990;186:745-50.
39. Tavassoli FA. Diseases of the nipple. En: Pathology of the breast. Norwalk, CT: Appleton & Lange, 1992;565-92.
40. Martin SA, Perez-Reyes N, Mendelsohn G. Angioinvasion in breast carcinoma. An immunohistochemical study of factor VIII-related antigen. Cancer 1987;59:1918-22.
41. Lee AKC, DeLellis RA, Silverman ML, Heatley GJ, Wolfe HJ. Prognostic significance of peritumoral lymphatic and blood vessel invasion in node negative carcinoma of the breast. J Clin Oncol 1990;8:1457-65.
42. Lancer HA, Moschella SL. Paget's disease of the male breast. J Am Acad Dermatol 1982;7:393-6.
43. Norris HJ, Taylor HB. Carcinoma of the male breast. Cancer 1969;23:1428-35.
44. Crichlow RW, Czernobilsky B. Paget's disease of the male breast. Cancer 1969;24:1033-40.
45. Gupta S, Khanna NN, Khanna S, Gupta S. Paget's disease of the male breast: a clinicopathologic study and a collective review. J Surg Oncol 1983;22:151-6.
46. Satiani B, Powell RW, Mathews WH. Paget disease of the male breast. Arch Surg 1977;112:587-92.
47. Hultborn R, Friberg S, Hultborn KA. Male breast carcinoma. I. A study of the total material reported to the Swedish Cancer Registry 1958-1967 with respect to clinical and histopathologic parameters. Acta Oncologica 1987;26:241-56.
48. Scheike O. Male breast cancer. Acta Pathol Microbiol Scand 1975;251 (suppl A):3-35.
49. Michaels MM, Craig CN, Roses DF. Lobular carcinoma of the male breast. Surgery 1994;115:402-5.
50. Salvadori B, Saccozzi R, Manzari A, Andreola S, Conti RA, Cusumano F, et al. Prognosis of breast cancer in males: an analysis of 170 cases. Eur J Cancer 1994;30A:930-5.
51. Slamon DJ, Clark GM, Wong SG, Levin WJ, Ullrich A, McGuire WL. Human breast cancer: correlation of relapse and survival with amplification of the HER-2/neu oncogene. Science 1987;235:177-82.
52. Toikkanen S, Helin H, Isola J, Joensuu H. Prognostic significance of HER-2 oncoprotein expression in breast cancer: a 30-year follow up. J Clin Oncol 1992;8:103-12.
53. Muss HB, Thor AD, Berry DA, Kute T, Lui ET, Koerner F, et al. c-erbB-2 expression and response to adjuvant therapy in women with node positive early breast cancer. N Engl J Med 1994;330:1260-6.
54. Fox SB, Day CA, Rogers S. Lack of c-erbB-2 oncoprotein expression in male breast carcinoma. J Clin Pathol 1991;44:960-1.
55. Hollstein M, Sidransky D, Vogelstein B, Harris CC. p53 mutations in human cancers. Science 1991;253:49-53.
56. Moll UM, Riou G, Levine AJ. Two distinct mechanisms alter p53 in breast cancer: mutation and nuclear exclusion. Proc Natl Acad Sci USA 1992;89:7262-6.
57. Cattoretti G, Rilke F, Andreola S, D'Amato L, Delia D. p53 expression in breast cancer. Int J Cancer 1988;41:178-83.
58. Thor AD, Moore DH II, Edgerton SM, Kawasaki ES, Reihsaus E, Lynch HT, et al. Accumulation of p53 tumor suppressor gene protein: an independent marker of prognosis in breast cancers. J Natl Cancer Inst 1992;84:845-55.
59. Guinee VF, Olsson H, Moller T, Shallenberger RC, van den Blink JW, Peter Z, et al. The prognosis of breast cancer in males: a report of 335 cases. Cancer 1993;71:154-61.
60. Elston CW. The assessment of histological differentiation in breast cancer. Aust N Z J Surg 1984;54:11-5.